| Literature DB >> 34011043 |
Li-Li Wang1,2, Jun-Feng Li1,3, Jun-Qiang Lei1,2, Shun-Lin Guo1,2, Jin-Kui Li1,2, Yong-Sheng Xu1,2, Yu Dou1,2.
Abstract
ABSTRACT: The aim of the study was to assess the potential role of preoperative gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) dynamic enhanced MR imaging for diagnosing microvascular invasion (MVI) and pathological grade of hepatocellular carcinoma (HCC).A total of 113 consecutive HCC patients confirmed by histopathology underwent preoperative Gd-EOB-DTPA dynamic enhanced MRI were included. Signal intensity (SI) of peritumoral, normal liver tissue and tumor parenchyma during arterial phase and hepatobiliary phase (HBP) were analyzed. The receiver operating characteristic (ROC) curves were performed to assess the potential diagnostic capability for MVI and pathological grade of HCC. Kaplan-Meier method was performed to estimate the recurrence-free survival rate and compared using the log rank test.SI ratio of peritumoral tissue to normal liver in arterial phase (SIAp/Al) was independently associated with MVI [odds ratio (OR) = 3.115, 95% confidence interval (CI): 1.867-5.198] and pathological grades (OR = 1.437, 95% CI: 1.042-1.981). The area under the curve (AUC) of SIAp/Al was equivalent to the SI of tumor parenchyma on arterial phase (SIAt) in distinguishing low and high pathological grades. However, the AUC of SIAp/Al (0.851) was larger than peritumoral hypointensity on HBP (0.668) for distinguishing MVI. The recurrence-free survival rate of HCC patients with SIAp/Al<1.1 was higher than HCC with SIAp/Al≥1.1(P = .025).The SIAp/Al in preoperative Gd-EOB-DTPA dynamic enhanced MR imaging is a potential diagnosis marker for MVI and pathological grade of HCC noninvasively. The higher SIAp/Al may predict the poor prognosis of HCC after surgery.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34011043 PMCID: PMC8136999 DOI: 10.1097/MD.0000000000025804
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1Flow chart of the enrolled patients for the study. FNH = focal nodular hyperplasia, ICC = intrahepatic cholangiocarcinoma, MVI = microvascular invasion, RFA = radiofrequency ablation, TACE = transcatheter arterial chemoembolization.
Baseline characteristics of clinical and pathological findings.
| Variable | Value |
| Clinical information | |
| Age(y)∗ | 52 (36–79) |
| Mean(y)† | 54.22 ± 8.68 |
| Male sex,n(%) | 87 (77.0) |
| Age(y)∗ | 52 (40–79) |
| Mean age (y)† | 54.47 ± 8.37 |
| Female sex,n (%) | 26 (23.0) |
| Age (y)∗ | 53.38 ± 9.88 |
| Mean age (y)† | 52.50 (36–73) |
| Origin of liver disease, n (%) | |
| Hepatitis B | 97 (85.8) |
| Hepatitis C | 7 (6.2) |
| Normal | 8 (7.1) |
| Hepatic steatosis | 1 (0.9) |
| ICG-R15,%∗ | 5.45 (0.40–39.50) |
| MELD Score∗ | 5.96 (0.08–31.75) |
| Child-Pugh class, n (%) | |
| A | 101 (89.4) |
| B | 12 (10.6) |
| AFP (ng/mL), n (%) | |
| ≤20 | 63 (55.8) |
| >20 | 50 (44.2) |
| Pathological findings | |
| Cirrhosis, n (%) | |
| Present | 106 (93.8) |
| Absent | 7 (6.2) |
| MVI status, n (%) | |
| MVI positive | 50 (44.3) |
| MVI negative | 63 (55.7) |
| Ki67, n (%) | |
| ≤50 | 99 (87.6) |
| >50 | 14 (12.4) |
| Edmondson–Steiner grade, n (%) | |
| G1-G2 | 68 (60.2) |
| G3-G4 | 45 (39.8) |
| Fibrosis stage, n (%) | |
| S1-S2 | 93 (82.3) |
| S3-S4 | 20 (17.7) |
Comparisons of parameters between different MVI and pathological groups.
| MVI status | Edmondson-Steiner grades | |||||
| Parameters | MVI-positive(n = 50) | MVI-negative(n = 63) | Low-grade (G1–G2)(n = 68) | High-grade (G3–G4)(n = 45) | ||
| Clinical information | ||||||
| Age (y) | 52.78 ± 8.85 | 55.37 ± 8.44 | .116 | 54.6 ± 9.25 | 53.64 ± 7.81 | .568 |
| Gender, n (%) | .824 | .872 | ||||
| Male | 38 (76.0) | 49 (77.8) | 52 (76.5) | 35 (77.8) | ||
| Female | 12 (24.0) | 14 (22.2) | 16 (23.5) | 10 (22.2) | ||
| Origin of liver disease, n (%) | .649 | .681 | ||||
| Hepatitis B | 44 (88.0) | 53 (84.1) | 58 (85.3) | 39 (86.7) | ||
| Hepatitis C | 2 (4.0) | 5 (7.9) | 5 (7.4) | 2 (4.4) | ||
| Normal | 4 (8.0) | 4 (6.3) | 5 (7.4) | 3 (6.7) | ||
| Hepatic steatosis | 0 (0.0) | 1 (1.7) | 0 (0.0) | 1 (2.2) | ||
| ICG-R15, % | 6.73 ± 5.09 | 8.15 ± 7.75 | .265 | 8.29 ± 7.40 | 6.35 ± 5.40 | .134 |
| MELD Score | 5.72 ± 2.82 | 7.14 ± 4.83 | .069 | 6.66 ± 4.67 | 6.28 ± 3.13 | .634 |
| Child-Pugh class, n (%) | .421 | .627 | ||||
| A | 46 (92.0) | 55 (87.3) | 60 (88.2) | 41 (91.1) | ||
| B | 4 (8.0) | 8 (12.7) | 8 (11.8) | 4 (8.9) | ||
| AFP (ng/mL), n (%) | .063 | .018 | ||||
| ≤20 | 23 (46.0) | 40 (63.5) | 44 (64.7) | 19 (42.2) | ||
| >20 | 27 (54.0) | 23 (36.5) | 24 (35.3) | 26 (57.8) | ||
| Pathological findings | ||||||
| Cirrhosis, n (%) | .639 | .305 | ||||
| Present | 48 (96.0) | 58 (92.1) | 62 (91.2) | 44 (97.8) | ||
| Absent | 2 (4.0) | 5 (7.9) | 6 (8.8) | 1 (2.2) | ||
| Ki67, n (%) | .299 | <.001 | ||||
| ≤50 | 42 (84.0) | 57 (90.5) | 67 (98.5) | 32 (71.1) | ||
| >50 | 8 (16.0) | 6 (9.5) | 1 (1.5) | 13 (28.9) | ||
| Fibrosis stage, n (%) | .359 | .602 | ||||
| S1-S2 | 43 (86.0) | 50 (79.4) | 57 (83.8) | 36 (80.0) | ||
| S3-S4 | 7 (14.0) | 13 (20.6) | 11 (16.2) | 9 (20.0) | ||
| MR imaging features | ||||||
| Maximum diameter (cm), n (%) | .849 | .003 | ||||
| ≤2 | 14 (28.0) | 15 (23.8) | 22 (32.4) | 7 (15.6) | ||
| >2 and ≤5 | 23 (46.0) | 32 (50.8) | 36 (52.9) | 19 (42.2) | ||
| >5 | 13 (26.0) | 16 (25.4) | 10 (14.7) | 19 (42.2) | ||
| Number, n (%) | .985 | .54 | ||||
| Solitary tumor | 42 (84.0) | 53 (84.1) | 56 (82.4) | 39 (86.7) | ||
| ≥Two tumors | 8 (16.0) | 10 (15.9) | 12 (17.6) | 6 (13.3) | ||
| Capsule integrity, n (%) | .427 | .005 | ||||
| Complete | 9 (18.0) | 16 (25.4) | 18 (26.5) | 7 (15.6) | ||
| Incomplete | 24 (48.0) | 23 (36.5) | 20 (29.4) | 27 (60.0) | ||
| Absent | 17 (34.0) | 24 (38.1) | 30 (44.1) | 11 (24.4) | ||
| SIAp | 295.58 ± 71.47 | 254.77 ± 72.33 | .003 | 273.15 ± 73.84 | 272.33 ± 76.23 | .955 |
| SIAp/Al | 1.11 ± 0.14 | 0.94 ± 0.12 | <.001 | 0.98 ± 0.14 | 1.06 ± 0.16 | .007 |
| SIAt | 280.58 ± 87.71 | 305.42 ± 84.60 | .132 | 313.88 ± 87.81 | 265.04 ± 76.38 | .003 |
| SIHp | 350.61 ± 76.22 | 371.71 ± 98.22 | .214 | 365.90 ± 97.72 | 357.06 ± 75.88 | .609 |
| SIHp/Hl | 0.90 ± 0.40 | 0.90 ± 0.20 | .995 | 0.92 ± 0.36 | 0.88 ± 0.19 | .472 |
| SIHt | 254.76 ± 65.65 | 277.56 ± 85.15 | .121 | 281.99 ± 86.96 | 245.55 ± 54.90 | .014 |
| Peritumoral hypointensity on HBP, n (%) | <.001 | .606 | ||||
| Present | 39 (78.0) | 28 (44.4) | 39 (57.4) | 28 (62.2) | ||
| Absent | 11 (22.0) | 35 (55.6) | 29 (42.6) | 17 (37.8) | ||
The correlation analysis between parameters and different MVI or pathological groups.
| MVI status | Edmondson–Steiner grades | |||
| Variable | R | r | ||
| AFP (ng/mL) | 0.222 | .018 | ||
| Ki67 | 0.407 | <.001 | ||
| Maximum diameter (cm) | 0.303 | .001 | ||
| Capsule integrity | −0.076 | .423 | ||
| SIAp | 0.332 | <.001 | ||
| SIAp/Al | 0.607 | <.001 | 0.257 | .006 |
| SIAt | −0.257 | .006 | ||
| SIHt | −0.177 | .061 | ||
| Peritumoral hypointensity on HBP | −0.339 | <.001 | ||
Univariate and multivariate logistic regression analysis between MR imaging features and MVI.
| Univariate analysis | Multivariate analysis | |||||
| Parameters | OR | 95% CI | OR | 95% CI | ||
| Maximum diameter (cm) | 1.149 | 0.409,3.226 | .85 | |||
| Number | 0.991 | 0.359,2.731 | .985 | |||
| Capsule integrity | 1.473 | 0.633,3.428 | .429 | |||
| SIAp | 1.008 | 1.002,1.014 | .006∗ | 1.003 | 0.996,1.009 | .411 |
| SIAp/Al | 3.603 | 2.106,6.162 | <.001∗ | 3.115 | 1.867,5.198 | <.001 |
| SIAt | 0.997 | 0.992,1.001 | .132 | |||
| SIHp | 0.997 | 0.993,1.002 | .214 | |||
| SIHp/Hl | 1.004 | 0.292,3.448 | .995 | |||
| SIHt | 0.996 | 0.991,1.001 | .128 | |||
| Peritumoral hypointensity on HBP | 4.432 | 1.926,10.199 | <.001∗ | 3.314 | 1.226,8.962 | .018 |
Figure 2The ROC curves of radiological features for MVI and pathological grade. (A), The ROC curves of SIAp/Al and peritumoral hypointensity on HBP for assessment MVI, the AUC was 0.851, 0.668. (B), The ROC curves of SIAt and SIAp/Al for differentiating pathological grade, the value of AUC was 0.652, 0.652. ROC = receiver operating characteristic, AUC = area under the receiver operating characteristic.
Diagnostic value of Gd-EOB-DTPA MR imaging parameters in differentiating the MVI and the pathological grade of HCC.
| Group | AUC | Cutoff value | Sensitivity | Specificity | PPV | NPV | |
| MVI-positive vs MVI-negative | |||||||
| SIAp/Al | 0.851 | <.001 | 1.005 | 0.840 | 0.794 | 76.400 | 86.200 |
| Peritumoral hypointensity on HBP | 0.668 | .002 | 0.50 | 0.780 | 0.556 | 58.200 | 76.100 |
| Low-grade vs High-grade | |||||||
| SIAp/Al | 0.652 | .003 | 1.089 | 0.444 | 0.882 | 71.400 | 70.600 |
| SIAt | 0.652 | .006 | 347.72 | 0.911 | 0.338 | 47.700 | 85.200 |
Univariate and multivariate logistic regression analysis between MR imaging features and pathological grade.
| Univariate analysis | Multivariate analysis | |||||
| Parameters | OR | 95% CI | OR | 95% CI | ||
| Maximum diameter (cm) | 0.278 | 0.108,0.715 | .005∗ | 0.231 | 0.064,0.836 | .065 |
| Number | 1.393 | 0.482,4.028 | .541 | |||
| Capsule integrity | 3.682 | 1.496,9.064 | .007∗ | 2.721 | 0.993,7.458 | .045 |
| SIAp | 1.000 | 0.995,1.005 | .954 | |||
| SIAp/Al | 1.457 | 1.094,1.941 | .01∗ | 1.437 | 1.042,1.981 | .027 |
| SIAt | 0.993 | 0.988,0.998 | .005∗ | 0.993 | 0.987,0.999 | .013 |
| SIHp | 0.999 | 0.995,1.003 | .605 | |||
| SIHp/Hl | 0.590 | 0.138,2.534 | .478 | |||
| SIHt | 0.993 | 0.986,0.999 | .018∗ | 0.994 | 0.986,1.003 | .182 |
| Peritumoral hypointensity on HBP | 1.225 | 0.567,2.647 | .606 | |||
Figure 3Effect of SIAp/Al ≥1.1and SIAp/Al <1.1 on the recurrence-free survival rate of patients with HCC. HCC patients with SIAp/Al ≥1.1 vs. SIAp/Al <1.1, P =.025. Statistical significance was assessed with the log-rank test.
Figure 4A 56-year old man had HCC recurrence 8 months after surgery. (A) Gd-EOB-DTPA dynamic enhanced MR images show a 6.7 cm hypervascular mass with peritumoral enhancement (arrow) in hepatic segment VI. SIAp/Al is signal intensity ratio of peritumoral tissue (1) to normal liver (2) on arterial phase, the value is 1.34. (B) histopathology slice reveals high-grade HCC with MVI (haematoxylin-eosin stain; original magnification, ×200).